GlassScriptPhysician profile
Kimberly D Tope
NPI 1225169451
$15,636.99
in general payments reported to CMS, 2019-2025
62 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
See the full distribution for Oncology (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,160 · 2022: $4,699 · 2023: $4,167 · 2024: $3,367 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,877 · Consulting Fee: $645 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,876.88 |
| Consulting Fee | $645.00 |
| Education | $256.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,597.80 | 2021-2025 | Calquence, Enhertu, Lynparza |
| Daiichi Sankyo INC. | $1,569.17 | 2021-2025 | Enhertu, Datroway, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $1,290.60 | 2021-2025 | Opdivo, Reblozyl, Opdualag |
| Lilly USA, LLC | $1,263.32 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $654.56 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| Gilead Sciences, INC. | $649.58 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $570.61 | 2021-2025 | |
| Seagen INC. | $521.71 | 2021-2023 | Tukysa, Adcetris, Tivdak |
| Pfizer INC. | $490.75 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $475.70 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $473.64 | 2021-2025 | |
| Janssen Biotech, INC. | $425.54 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Abbvie INC. | $402.88 | 2022-2025 | |
| Amgen INC. | $378.33 | 2021-2023 | Lumakras |
| Merck Sharp & Dohme LLC | $344.52 | 2022-2024 | Keytruda, Lynparza |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $325.45 | 2021-2024 | Cabometyx |
| Incyte Corporation | $319.08 | 2022-2025 | Jakafi, Monjuvi |
| Eisai INC. | $306.93 | 2022-2025 | |
| Kite Pharma, INC. | $290.81 | 2021-2023 | Yescarta |
| Astellas Pharma US INC | $272.07 | 2022-2025 | Padcev, Xospata, Vyloy |
| Regeneron Healthcare Solutions, INC. | $243.60 | 2023-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $217.24 | 2021-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $215.72 | 2021-2024 | Zejula, Jemperli, Ojjaara |
| Puma Biotechnology, INC. | $176.95 | 2021-2025 | |
| Blueprint Medicines Corporation | $148.32 | 2022-2024 | Ayvakit |
| Beigene USA, INC. | $142.77 | 2021-2024 | Brukinsa, Tevimbra |
| Ipsen Biopharmaceuticals, INC | $141.20 | 2021-2023 | Onivyde, Somatuline Depot |
| Takeda Pharmaceuticals U.S.A., INC. | $137.10 | 2022-2024 | Alunbrig, Fruzaqla |
| Pharmacosmos Therapeutics INC. | $114.99 | 2023-2025 | Monoferric, Cosela |
| Mirati Therapeutics, INC. | $109.53 | 2023-2024 | Krazati |
| Epizyme, INC. | $108.47 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Array Biopharma INC | $85.79 | 2023-2024 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $70.83 | 2021-2022 | |
| Tersera Therapeutics LLC | $68.82 | 2024-2025 | Zoladex |
| Inari Medical, INC. | $57.86 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Csl Behring | $57.71 | 2021-2023 | Afstyla, Idelvion |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.44 | 2021-2023 | Gilotrif |
| Jazz Pharmaceuticals INC. | $53.15 | 2022-2025 | |
| Legend Biotech USA INC. | $52.00 | 2024-2025 | Carvykti |
| Dendreon Pharmaceuticals LLC | $49.90 | 2022-2023 | Provenge |
| Sobi, INC | $48.18 | 2024 | |
| Servier Pharmaceuticals LLC | $46.49 | 2024 | |
| Karyopharm Therapeutics INC. | $46.21 | 2021-2024 | Xpovio |
| Tg Therapeutics, INC. | $43.22 | 2021-2022 | |
| Genmab U.S., INC. | $42.99 | 2024 | Epkinly |
| Stemline Therapeutics INC. | $40.35 | 2023-2025 | Orserdu |
| Emmaus Medical, INC. | $35.21 | 2022 | |
| Morphosys, US INC. | $33.25 | 2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $32.48 | 2022-2023 | Fotivda |
| Deciphera Pharmaceuticals INC. | $30.44 | 2021-2022 | |
| Myovant Sciences INC. | $29.86 | 2022 | |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Emd Serono, INC. | $21.84 | 2024 | |
| Amag Pharmaceuticals, INC. | $20.61 | 2022 | |
| Ge Healthcare | $20.07 | 2022 | |
| Sumitomo Pharma America, INC. | $18.59 | 2024 | Orgovyx |
| Acceleron Pharma, INC. | $18.37 | 2021 | |
| Taiho Oncology, INC. | $14.27 | 2024 | |
| Cti Biopharma Corp. | $14.08 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $12.99 | 2021 | |
| Adc Therapeutics America, INC. | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Tope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.